GlobeNewswire·Nov 6, 2026, 9:48 AM ET

MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)

INKT

MiNK Therapeutics presented preclinical findings at the 41st SITC Annual Meeting in Phoenix regarding its allogeneic iNKT cell therapies, agenT-797 & MiNK-215.
In colorectal cancer liver metastasis models resistant to botensilimab & balstilimab alone, adding agenT-797 supported immune reprogramming & tumor-cell killing, validating an ongoing Phase 2 combination study.
Unmodified agenT-797 & FAP-targeted MiNK-215 cleared senescent cells linked to relapse & fibrotic disease, with MiNK-215 extending killing into the tumor stroma via FAP targeting.
Findings highlight immune mechanisms relevant to acute inflammation, cellular senescence, & tissue remodeling, supporting further investigation in MiNK's Phase 2 trial for acute hypoxemic respiratory failure/ARDS.
MiNK's off-the-shelf platform combines clinical-stage unmodified cell therapy with next-generation engineered candidates for scalable, cryopreserved delivery without patient-specific manufacturing.
In MSS colorectal cancer models, agenT-797 shifted suppressive immune populations to an immune-stimulatory phenotype & increased CD8 T-cell density when combined with botensilimab, balstilimab, & antigen-specific T cells.
The triple combination of agenT-797, botensilimab, & balstilimab increased tumor-cell apoptosis in models refractory to checkpoint inhibitors alone.
MiNK-215 eliminated senescent breast cancer cells & FAP-expressing lung fibroblasts, while senescent lung fibroblasts with elevated checkpoint ligands required antigen presentation strategies for elimination.
Loading the lipid antigen α-galactosylceramide restored agenT-797 killing of less-sensitive senescent fibroblasts, indicating resistance can be overcome through engineering or combination strategies.
These data reinforce the rationale for agenT-797 in a randomized Phase 2 trial for acute respiratory failure (NCT07615010) & for engineered iNKT therapies in fibroinflammatory conditions.

Company: MiNK Therapeutics
Keywords: Nasdaq:INKT, MiNK Therapeutics, $iNKT, INKT, agenT797, MINK215, ARDS, coloncancer, tcell, innovation